CVS Health (CVS) Price Target Raised to $90.00

CVS Health (NYSE:CVS) had its target price upped by equities research analysts at SunTrust Banks to $90.00 in a report released on Friday, The Fly reports. The firm presently has a “buy” rating on the pharmacy operator’s stock. SunTrust Banks’ target price would indicate a potential upside of 19.79% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on CVS. Morgan Stanley raised shares of CVS Health from an “equal weight” rating to an “overweight” rating in a research report on Friday. ValuEngine cut shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Vetr lowered shares of CVS Health from a “buy” rating to a “hold” rating and set a $77.11 target price on the stock. in a report on Thursday. UBS Group upgraded shares of CVS Health from an “outperform” rating to a “strong-buy” rating in a report on Thursday. Finally, Raymond James Financial upgraded shares of CVS Health from an “outperform” rating to a “strong-buy” rating and set a $90.00 target price on the stock in a report on Thursday. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $86.34.

CVS Health (CVS) opened at $75.13 on Friday. The stock has a market cap of $74,151.01, a PE ratio of 15.52, a PEG ratio of 1.29 and a beta of 0.90. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. CVS Health has a 1 year low of $66.45 and a 1 year high of $84.72.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion for the quarter, compared to analysts’ expectations of $46.17 billion. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The business’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.64 EPS. research analysts forecast that CVS Health will post 5.9 earnings per share for the current fiscal year.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.61% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fieldpoint Private Securities LLC raised its position in shares of CVS Health by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 1,000 shares in the last quarter. Wealthcare Advisory Partners LLC raised its position in shares of CVS Health by 330.3% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 991 shares in the last quarter. Arcadia Investment Management Corp MI raised its position in shares of CVS Health by 119.6% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after buying an additional 726 shares in the last quarter. MPS Loria Financial Planners LLC purchased a new stake in shares of CVS Health during the 2nd quarter valued at $119,000. Finally, Gemmer Asset Management LLC raised its position in shares of CVS Health by 15.3% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock valued at $121,000 after buying an additional 200 shares in the last quarter. 81.63% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/05/cvs-health-cvs-price-target-raised-to-90-00.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

The Fly

Analyst Recommendations for CVS Health (NYSE:CVS)

Leave a Reply